» Articles » PMID: 9700324

The Street Value of Prescription Drugs

Overview
Journal CMAJ
Date 1998 Aug 13
PMID 9700324
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although most physicians are aware of the potential for abuse and resale of prescribed medications, little has been done to document it. The purpose of this study was to determine which prescription drugs have street value, what that value is and why these drugs are used.

Methods: A descriptive cross-sectional survey using a semistructured interview technique was carried out on 2 weekdays (Mar. 10 and Apr. 1, 1997) in Vancouver's Downtown Eastside. A total of 58 users and dealers of prescription sedative/hypnotic and narcotic drugs were approached. Information collected included the demographic characteristics of those interviewed, the common street names of the drugs of interest, and their value and method of use.

Results: Thirty-two people agreed to participate in the study (participation rate 55%), 7 of whom were dealers. The range in price of sedative/hypnotic drugs was $0.10 to $2. For narcotic drugs the range was much greater, at $0.25 to $75. Descriptive analysis identified the minimum and maximum price and the mode of each preparation. Among the weak narcotic drugs the index drug (highest in demand on the street) was Tylenol No. 3 and among the more potent narcotics, MS Contin 30 mg.

Interpretation: A wide variety of prescription sedative/hypnotic and narcotic drugs are available on the street. The mark-up from pharmacy cost can be considerable. Factors influencing pricing include the relative inexperience of the buyer, the availability of illicit narcotics, the current street supply of prescription medications and the time of the month (before or after issue of social assistance cheques).

Citing Articles

A Prospective Analysis of Opioid Prescription, Consumption, and Psychometric Correlations in Outpatient Plastic Surgery Procedures.

Barkho J, Leveille C, Pozdnyakov A, Faragalla K, Sengupta N, Wong C Plast Surg (Oakv). 2025; 33(1):59-67.

PMID: 39876852 PMC: 11770726. DOI: 10.1177/22925503231201634.


Dynamics of combatting market-driven epidemics: Insights from U.S. reduction of cigarette, sugar, and prescription opioid consumption.

Rimanyi E, Quick J, Yamey G, Immurana M, Malik V, Doherty T PLOS Glob Public Health. 2024; 4(7):e0003479.

PMID: 39047013 PMC: 11268728. DOI: 10.1371/journal.pgph.0003479.


Investigation of the Incidence and Geographic Distribution of Bone and Soft Tissue Sarcomas in Canada: A National Population-Based Study.

Alkazemi B, Ghazawi F, Lagace F, Nechaev V, Zubarev A, Litvinov I Curr Oncol. 2023; 30(6):5631-5651.

PMID: 37366907 PMC: 10297017. DOI: 10.3390/curroncol30060424.


On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data.

Pappin J, Bavli I, Herder M Clin Trials. 2022; 19(5):584-590.

PMID: 35924783 PMC: 9523806. DOI: 10.1177/17407745221108436.


Leveraging black-market street buprenorphine pricing to increase capacity to treat opioid addiction, 2010-2018.

Hswen Y, Zhang A, Brownstein J Prev Med. 2020; 137:106105.

PMID: 32353575 PMC: 7333912. DOI: 10.1016/j.ypmed.2020.106105.


References
1.
Finch J . Prescription drug abuse. Prim Care. 1993; 20(1):231-9. View